{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:33:53Z","timestamp":1794317633736,"version":"4.9.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jacc.2025.05.060","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T14:06:46Z","timestamp":1754316406000},"page":"426-439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Outcomes in Older Patients After Switching to a Newer Anticoagulant or Remaining on Warfarin"],"prefix":"10.1016","volume":"86","author":[{"given":"Andre M.","family":"Nicolau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8977-6929","authenticated-orcid":false,"given":"Andre","family":"Zimerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Afilalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Gencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Steffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Palazzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Eikelboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manesh R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard J.","family":"Gersh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belal","family":"Suleiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris R.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio I.","family":"Scanavacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian T.","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott M.","family":"Antman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2025.05.060_bib1","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation","volume":"138","author":"Pisters","year":"2010","journal-title":"CHEST J"},{"issue":"8","key":"10.1016\/j.jacc.2025.05.060_bib2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","article-title":"Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study","volume":"27","author":"Heeringa","year":"2006","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacc.2025.05.060_bib3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/ehjcvp\/pvz061","article-title":"Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial","volume":"6","author":"Nicolau","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2025.05.060_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/agm2.12214","article-title":"Frailty and oral anticoagulant prescription in adults with atrial fibrillation: a systematic review","author":"Bul","year":"2023","journal-title":"Aging Med"},{"issue":"8","key":"10.1016\/j.jacc.2025.05.060_bib5","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2459\/JCM.0000000000000986","article-title":"Direct oral anticoagulants for patients aged over 80 years in nonvalvular atrial fibrillation: The impact of frailty","volume":"21","author":"De Simone","year":"2020","journal-title":"J Cardiovasc Med"},{"key":"10.1016\/j.jacc.2025.05.060_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.archger.2018.12.013","article-title":"Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: a systematic review with meta-analysis and trial sequential analysis","volume":"81","author":"Caldeira","year":"2019","journal-title":"Arch Gerontol Geriatr"},{"issue":"12","key":"10.1016\/j.jacc.2025.05.060_bib7","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1055\/s-0042-1756355","article-title":"Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF Registry Phase II and III","volume":"122","author":"Romiti","year":"2022","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.jacc.2025.05.060_bib8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/STROKEAHA.123.044407","article-title":"Net clinical benefit of oral anticoagulation among frail patients with atrial fibrillation: nationwide cohort study","volume":"55","author":"S\u00f8gaard","year":"2024","journal-title":"Stroke"},{"issue":"6","key":"10.1016\/j.jacc.2025.05.060_bib9","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.hrthm.2021.02.018","article-title":"Oral anticoagulants in extremely-high-risk, very elderly (>90 years) patients with atrial fibrillation","volume":"18","author":"Chao","year":"2021","journal-title":"Heart Rhythm"},{"issue":"4","key":"10.1016\/j.jacc.2025.05.060_bib10","first-page":"279","article-title":"Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial","volume":"149","author":"Joosten","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.05.060_bib11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ahj.2020.12.002","volume":"233","author":"Carnicelli","year":"2021","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.jacc.2025.05.060_bib12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jacc.2025.05.060_bib13","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.amjcard.2019.02.060","article-title":"Meta-analysis of direct-acting oral anticoagulants compared with warfarin in patients >75 years of age","volume":"123","author":"Malik","year":"2019","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.jacc.2025.05.060_bib14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12916-020-01870-w","article-title":"Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial","volume":"18","author":"Wilkinson","year":"2020","journal-title":"BMC Med"},{"issue":"11","key":"10.1016\/j.jacc.2025.05.060_bib15","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jacc.2016.06.034","article-title":"Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 Analysis","volume":"68","author":"Steffel","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.05.060_bib16","article-title":"Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial","volume":"353","author":"Jaspers","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jacc.2025.05.060_bib17","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.115.018544","article-title":"Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation","volume":"133","author":"Piccini","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.05.060_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ahj.2021.12.017","article-title":"Edoxaban versus warfarin in high-risk patients with atrial fibrillation: a comprehensive analysis of high-risk subgroups","volume":"247","author":"Gencer","year":"2022","journal-title":"Am Heart J"},{"issue":"36","key":"10.1016\/j.jacc.2025.05.060_bib19","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.05.060_bib20","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/CIRCULATIONAHA.123.067555","article-title":"Switching to direct anticoagulation or continued vitamin-K antagonists in frail patients with atrial fibrillation in whom vitamin-K antagonists are tolerated?","author":"Wallentin","year":"2024","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacc.2025.05.060_bib21","doi-asserted-by":"crossref","DOI":"10.36660\/abc.20230671i","article-title":"Frailty and atrial fibrillation: a closer look at the FRAIL-AF Trial","volume":"121","author":"Ferreira","year":"2024","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.jacc.2025.05.060_bib22","first-page":"1377","article-title":"FRAIL-AF study: more bleeding with DOACs compared with VKAs in patients with frailty?","author":"Godoy","year":"2024","journal-title":"Can J Cardiol"},{"issue":"9","key":"10.1016\/j.jacc.2025.05.060_bib23","first-page":"1046","article-title":"Conceptual models of frailty: accumulation of deficits","volume":"32","author":"Rockwood","year":"2016","journal-title":"Can J Cardiol"},{"issue":"7","key":"10.1016\/j.jacc.2025.05.060_bib24","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/gerona\/62.7.722","article-title":"Unconventional views of frailty review article frailty in relation to the accumulation of deficits","volume":"62A","author":"Rockwood","year":"2007","journal-title":"J Gerontol"},{"issue":"24","key":"10.1016\/j.jacc.2025.05.060_bib25","article-title":"A standard procedure for creating a frailty index","volume":"8","author":"Searle","year":"2008","journal-title":"BMC Geriatr"},{"issue":"7","key":"10.1016\/j.jacc.2025.05.060_bib26","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1161\/CIRCULATIONAHA.123.064003","article-title":"The effect of frailty on the efficacy and safety of intensive blood pressure control: a post hoc analysis of the SPRINT Trial","volume":"148","author":"Du","year":"2023","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacc.2025.05.060_bib27","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1161\/STROKEAHA.122.041891","article-title":"Higher hospital frailty risk score is associated with increased risk of stroke: observational and genetic analyses","volume":"54","author":"Renedo","year":"2023","journal-title":"Stroke"},{"issue":"6","key":"10.1016\/j.jacc.2025.05.060_bib28","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra2301292","article-title":"Frailty in older adults","volume":"391","author":"Kim","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.05.060_bib29","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.jacc.2025.05.060_bib30","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/STROKEAHA.120.028825","article-title":"Comparative safety and effectiveness of oral anticoagulants in nonvalvular atrial fibrillation: the NAXOS Study","volume":"51","author":"Van Ganse","year":"2020","journal-title":"Stroke"},{"issue":"24","key":"10.1016\/j.jacc.2025.05.060_bib31","doi-asserted-by":"crossref","first-page":"7423","DOI":"10.3390\/jcm11247423","article-title":"Oral anticoagulant use and appropriateness in elderly patients with atrial fibrillation in complex clinical conditions: ACONVENIENCE Study","volume":"11","author":"Bonanad","year":"2022","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.jacc.2025.05.060_bib32","first-page":"407","article-title":"Which anticoagulant is safest for frail elderly patients with nonvalvular A-fib?","volume":"71","author":"Earwood","year":"2022","journal-title":"J Fam Pract"},{"issue":"9","key":"10.1016\/j.jacc.2025.05.060_bib33","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.7326\/M20-7141","article-title":"Frailty and clinical outcomes of direct oral anticoagulants versus warfarin in older adults with atrial fibrillation","volume":"174","author":"Kim","year":"2021","journal-title":"Ann Intern Med"},{"issue":"18","key":"10.1016\/j.jacc.2025.05.060_bib34","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N Engl J Med"},{"issue":"9028","key":"10.1016\/j.jacc.2025.05.060_bib35","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(96)03487-3","article-title":"Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial","volume":"348","year":"1996","journal-title":"Lancet"},{"issue":"8882","key":"10.1016\/j.jacc.2025.05.060_bib36","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","article-title":"Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke","volume":"342","year":"1993","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jacc.2025.05.060_bib37","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1007\/s00392-014-0742-y","article-title":"Adherence to warfarin treatment among patients with atrial fibrillation","volume":"103","author":"Skeppholm","year":"2014","journal-title":"Clin Res Cardiol"},{"issue":"7","key":"10.1016\/j.jacc.2025.05.060_bib38","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/clc.23376","article-title":"Switching warfarin to direct oral anticoagulants in atrial fibrillation: insights from the NCDR PINNACLE registry","volume":"43","author":"Sciria","year":"2020","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacc.2025.05.060_bib39","first-page":"e21","article-title":"Choosing between continuing vitamin K antagonists (VKA) or switching to a direct oral anticoagulant in currently well-controlled patients on VKA for atrial fibrillation: a randomised controlled trial (GAInN)","author":"van Miert","year":"2019","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.jacc.2025.05.060_bib40","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s43587-021-00099-3","article-title":"The degree of frailty as a translational measure of health in aging","volume":"1","author":"Howlett","year":"2021","journal-title":"Nat Aging"},{"issue":"10","key":"10.1016\/j.jacc.2025.05.060_bib41","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1111\/jgs.18453","article-title":"A crosswalk of commonly used frailty scales","volume":"71","author":"Sison","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"10.1016\/j.jacc.2025.05.060_bib42","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jamda.2013.03.022","article-title":"Frailty consensus: a call to action","volume":"14","author":"Morley","year":"2013","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.jacc.2025.05.060_bib43","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2016.14356","article-title":"Direct oral anticoagulants in the elderly: systematic review and meta-analysis of evidence, current and future directions","volume":"146","author":"Sadlon","year":"2016","journal-title":"Swiss Med Wkly"},{"issue":"22","key":"10.1016\/j.jacc.2025.05.060_bib44","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.3390\/jcm10225268","article-title":"Direct oral anticoagulants versus warfarin in octogenarians with nonvalvular atrial fibrillation: A systematic review and meta-analysis","volume":"10","author":"Bonanad","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.jacc.2025.05.060_bib45","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12959-024-00608-5","article-title":"Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation combined with chronic kidney disease: a systematic review and meta-analysis","volume":"22","author":"Li","year":"2024","journal-title":"Thromb J"},{"issue":"8","key":"10.1016\/j.jacc.2025.05.060_bib46","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1161\/STROKEAHA.120.028934","article-title":"Direct-acting oral anticoagulants versus warfarin in medicare patients with chronic kidney disease and atrial fibrillation","volume":"51","author":"Wetmore","year":"2020","journal-title":"Stroke"},{"issue":"10","key":"10.1016\/j.jacc.2025.05.060_bib47","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1161\/STROKEAHA.120.033470","article-title":"Clinical outcomes in atrial fibrillation patients with a history of cancer treated with non-vitamin K antagonist oral anticoagulants: a nationwide cohort study","volume":"52","author":"Chan","year":"2021","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.jacc.2025.05.060_bib48","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1161\/STROKEAHA.120.030761","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and prior gastrointestinal bleeding","volume":"52","author":"Kwon","year":"2021","journal-title":"Stroke"},{"issue":"10","key":"10.1016\/j.jacc.2025.05.060_bib49","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jamaneurol.2019.2099","article-title":"Clinical effectiveness of direct oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke: findings from the patient-centered research into outcomes stroke patients prefer and effectiveness research (PROSPER) study","volume":"76","author":"Xian","year":"2019","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.jacc.2025.05.060_bib50","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"10.1016\/j.jacc.2025.05.060_bib51","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12877-019-1042-1","article-title":"FRAILTOOLS study protocol: a comprehensive validation of frailty assessment tools to screen and diagnose frailty in different clinical and social settings and to provide instruments for integrated care in older adults","volume":"19","author":"Checa-L\u00f3pez","year":"2019","journal-title":"BMC Geriatr"},{"issue":"1","key":"10.1016\/j.jacc.2025.05.060_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5582\/irdr.2023.01113","article-title":"Global frailty screening tools: review and application of frailty screening tools from 2001 to 2023","volume":"13","author":"Deng","year":"2024","journal-title":"Intractable Rare Dis Res"},{"key":"10.1016\/j.jacc.2025.05.060_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.archger.2022.104661","article-title":"Frailty and outcomes in older adults with non-valvular atrial fibrillation from the ANAFIE registry","volume":"101","author":"Akishita","year":"2022","journal-title":"Arch Gerontol Geriatr"},{"issue":"4","key":"10.1016\/j.jacc.2025.05.060_bib54","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s11606-021-06834-1","article-title":"Prevalence of frailty and associations with oral anticoagulant prescribing in atrial fibrillation","volume":"37","author":"Sanghai","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"4","key":"10.1016\/j.jacc.2025.05.060_bib55","first-page":"268","article-title":"Clinical characteristics and type of antithrombotic treatment in a Spanish cohort of elderly patients with atrial fibrillation according to dependency, frailty and cognitive impairment","volume":"15","author":"Mostaza","year":"2018","journal-title":"J Geriatr Cardiol"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725067178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725067178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T02:51:14Z","timestamp":1786503074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725067178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0735109725067178"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.05.060","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes in Older Patients After Switching to a Newer Anticoagulant or Remaining on Warfarin","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.05.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}